NASDAQ: HINDVyome Holdings Inc Stock
$2.13-0.02 (-0.93%)
Updated Apr 2, 2026
HIND Price
$2.13
Fair Value Price
$2.05
Market Cap
$14.95M
52 Week Low
$1.75
52 Week High
$69.77
P/E
-0.44x
P/B
3.97x
P/S
23.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$319.71k
Earnings
-$10.26M
Gross Margin
68.4%
Operating Margin
-3,163.88%
Profit Margin
-3,209.7%
Debt to Equity
0.73
Operating Cash Flow
-$4M
Beta
0.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HIND Overview
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HIND's potential to beat the market
- HIND doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
HIND
RankedUnranked of 100
RankedUnranked of 100
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.97 | A | |
| $9.63 | A | |
| $24.60 | A |
Be the first to know about important HIND news, forecast changes, insider trades & much more!
HIND News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HIND scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HIND ($2.13) is overvalued by 3.67% relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HIND ($2.13) is not significantly undervalued (3.67%) relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HIND is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HIND due diligence checks available for Premium users.
Valuation
HIND fair value
Fair Value of HIND stock based on Discounted Cash Flow (DCF)
Price
$2.13
Fair Value
$2.05
Overvalued by
3.67%
HIND ($2.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HIND ($2.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HIND is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HIND price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.44x
Industry
23.94x
Market
30.13x
HIND price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.97x
Industry
3.27x
HIND is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HIND's financial health
Profit margin
Revenue
-$2.1M
Net Income
-$672.2k
Profit Margin
32.5%
HIND's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HIND's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.5M
Liabilities
$2.7M
Debt to equity
0.73
HIND's short-term assets ($5.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HIND's short-term assets ($5.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HIND's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HIND's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$0.0
Financing
$764.0k
HIND's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HIND vs Medical Device Stocks
Vyome Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.